Access widened to funded medicines

Last updated 05:00 13/11/2012

Relevant offers

Politics

Helen Clark continues to lag in new straw poll on next United Nations chief South Auckland motel residents 'pressured out' despite promises, tenant says No show from Education Minister at school union conference PM Key looking to underdog Trump to beat expectations in first debate with Clinton Greens won't stand candidate in any Mt Roskill by-election Auckland mayoral debate turns into shoving match between screaming candidates BMW and Charge Net to create 'electric highway' in NZ by 2018 My open letter to MP Louise Upston about dangerous dogs Neil Quigley replaces Rod Carr as chairman of the Reserve Bank of New Zealand John Key promotes Helen Clark. Andrew Little distances himself from her views. Say what?

Pharmac has spent more than $21.5 million on new drugs and widening access to publicly funded medicines in the past year.

Blood thinning drug Pradaxa, also known as dabigatran, was the most expensive new drug to be funded, with an estimated annual cost of $16 million.

Two new drugs targeting specific types of breast and kidney cancer were also added to the list of funded medications.

More people can access the drug rituximab, which is used to treat some kinds of lymphomas. Breast cancer drug docetaxel has also been made more widely available and access to funded treatment for Crohn's disease, Cystic fibrosis and asthma were widened.

The Government's drug-buying agency yesterday released its annual report for the year ending June 30, which showed 14 new medicines were funded in the past year and access to 10 others was widened.

An extra 56,840 patients were expected to benefit from the changes, on top of the record 3.3 million New Zealanders who received fully funded medication in the past year.

Pharmac stayed within its $777.4m budget in a year which saw it take on additional roles, including managing the national immunisation schedule and hospital medicines and medical devices.

It also contributed $379,000 towards a research trial in Finland looking at whether the nine week or 12-month duration of breast cancer drug Herceptin offers a better treatment.

Ad Feedback

- The Dominion Post

Special offers
Opinion poll

Where do you stand on political coat-tail riding?

If it gets marginalised voices into Parliament, I'm for it.

I'm against it - if you don't get the votes, you shouldn't be there.

It's just part of the political game.

Vote Result

Related story: Voters reject riding on the coat-tails

Featured Promotions

Sponsored Content